Healthcare / BiotechnologyTaipei Exchange
$37.00
-1.00 (-2.74%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $54.3M · quality 65.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$979M
P/E
24.3x
↑EV/EBITDA
14.0x
↑ROE
4.6%
↑Gross Margin
55.8%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-13.6%
FCF CAGR
+16.7%
FCF margin
55.2%
FCF / Net income
3.72x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $273.6M · net income $40.6M · FCF $150.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $273.6M | $273.6M | $347.5M | $333.9M | $424.0M |
| Net Income | $40.6M | $40.6M | $56.3M | $11.7M | $72.1M |
| EBITDA | $52.3M | $52.3M | $81.9M | $25.9M | $120.6M |
| EPS | — | — | 2.12 | 0.44 | 2.93 |
| Gross Margin | 55.8% | 55.8% | 58.7% | 52.3% | 57.4% |
| Operating Margin | 7.0% | 7.0% | 16.0% | 1.8% | 21.5% |
| Net Margin | 14.8% | 14.8% | 16.2% | 3.5% | 17.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 |
| Current Ratio | 9.27 | 9.27 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $150.9M | $150.9M | $54.3M | $14.7M | $95.1M |
| Returns | |||||
| ROE | 4.6% | 4.6% | 5.8% | 1.2% | 7.2% |
| Valuation | |||||
| P/E | 24.34 | 24.34 | 25.52 | 192.05 | 40.96 |
| EV/EBITDA | 14.05 | 14.05 | 16.34 | 59.81 | 16.75 |
| P/B | 1.10 | 1.10 | 1.47 | 2.27 | 2.94 |
| Growth & Yield | |||||
| Revenue Growth | -21.3% | -21.3% | 4.1% | -21.3% | — |
| EPS Growth | — | — | 381.8% | -85.0% | — |
| Dividend Yield | 5.6% | 5.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.4%
Start / end P/E
n/dx → n/dx
EPS bridge
2.12 → n/d
Residual
-17.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.